Novo Nordisk Lowers Prices on Obesity and Diabetes Drugs
Novo Nordisk, a leading pharmaceutical company, is making significant changes to its pricing strategy for popular obesity and diabetes drugs. In an effort to increase sales and fend off competition, the company has announced lower prices for its blockbuster medications. As of now, cash-paying patients can purchase Wegovy and Ozempic, two popular GLP-1 drugs, for … Read more